![logo](/logos/SANN.SW.webp)
Santhera Pharmaceuticals Holding AG
SIX:SANN.SW
9.22 (CHF) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Santhera Pharmaceuticals Holding AG |
Symbool | SANN.SW |
Munteenheid | CHF |
Prijs | 9.22 |
Beurswaarde | 108,055,938 |
Dividendpercentage | 0% |
52-weken bereik | 7.14 - 14.62 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Thomas Meier Ph.D. |
Website | https://www.santhera.com |
An error occurred while fetching data.
Over Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CHF)
Cijfers zijn in miljoenen (CHF)